BIBF 1120 is a triple tyrosin kinase inhibitor and a potent antagonist of growth factors such as platelet-derived growth factor, vascular endothelial growth factor and basic fibroblast growth factor, and it is currently evaluated in clinical trials as a potential IPF therapy. This evidence concerns the gene FGF2 and idiopathic pulmonary fibrosis.